The global Lyme disease diagnostics market size was valued at USD 894.09 Million in 2022 and is also projected to reach USD 1226.01 Million by 2028, is expected to grow at a compound annual growth rate (CAGR) of 6.5% from 2023 to 2028.
Lyme disease is a bacterial infection caused by species borrelia; this disease generally spreads in humans through infected tick bites. Symptoms such as depression, fever, fatigue, and skin rashes result from infected people with the disease. It can be treated with antibiotics only if the condition is diagnosed at the early stages of its occurrence. However, if the disease is left untreated, it affects the central nervous system, heart, and joints. The diagnostic technology is used in different laboratories includes lymphocytic transformation tests, urine antigen tests, immunofluorescent staining, and others. The technologies are developing to diagnose Lyme diseases with the help of blood samples. According to the reports of the Centers for disease control and prevention, it is reported that the number of cases of tick-borne was 47,743 leading to the adoption of Lyme disease diagnostic tests.
The global lyme disease diagnostics market is primarily driven by the increasing awareness about the novel techniques to diagnose lyme disease and identifying techniques of chronic Lyme infection from a blood sample.
The availability of these tests will improve the accuracy issue that plagued serology-based assays. The proliferation of Lyme disease is a key factor expected to drive the growth of the target market. Also, market participants' research and development activities are expected to boost the Lyme disease diagnostics market's growth potential.
Furthermore, the expanding government initiatives to upgrade medical healthcare facilities would aid the market's growth in the coming years. Besides, the rising number of tick-borne infectious illnesses, growing occurrences of novel forms of vector-borne diseases, and increasing healthcare spending are likely to propel the worldwide Lyme disease diagnostics market further. In partnership with the Centers for Disease Control and Prevention (CDC), the National Institute of Allergy and Infectious Diseases plays a critical role in supporting the development of innovative approaches to enhance Lyme disease screening. Moreover, NIAID grantees collaborate with the Centers for Disease Control and Prevention (CDC). However, leading market players are engaged in the research and development of novel tests for Lyme disease diagnosis, which is projected to help the global Lyme disease diagnostics market's growth. Many individuals with Lyme-like symptoms are misdiagnosed because current serological assays cannot reliably detect antibodies to all borrelia burgdorferi strains. As a result, there is a growing demand for improved illness diagnostic tests.
However, global Lyme disease diagnostics market expansion is constrained by a lack of public awareness about the condition and ineffective Lyme disease testing in undeveloped and emerging countries. The lack of Lyme disease therapy in rural regions has slowed the Lyme disease diagnostics market over the period.
Impact of COVID-19 on the global lyme disease diagnostics market:
The global pandemic coronavirus-19 (COVID-19) of 2020 has captivated healthcare experts' attention, impacting all aspects of treatment. The front end of all healthcare contacts now includes screening for COVID-19 symptoms (such as respiratory symptoms, fever, myalgia, and exhaustion). Because of COVID-19 pandemic-related changes in healthcare workflow and diagnostic reasoning, Lyme disease diagnosis was delayed in the spring of 2020. During the current COVID-19 epidemic, the COVID-19 outbreak has prompted a significant increase in the use of telemedicine in healthcare services. The effects of telemedicine in identifying acute infectious disorders like Lyme disease are unknown. Provide telemedicine to help diagnose Lyme disease and enable fast access to diagnosis and treatments. But it is expected to result in fewer ambulatory visits to outpatient doctors. A positive symptom screen triggers a prioritized process and evaluation, including COVID-19 testing and quarantine, depending on the results. Evaluation for other reasons of the patient's symptoms is frequently postponed throughout the quarantine period, risking delayed diagnosis and consequences.
Market Size Available
2022 to 2028
2023 to 2028
By Diagnostic Tests, Diagnostic Technologies, End User and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa.
This market research report on the global lyme disease diagnostics market has been segmented and sub-segmented into the following categories.
Lyme disease diagnostics market - By Diagnostic Tests:
Urine Antigen Tests
Lymphocytic Transformation Test
Based on the diagnostic test, the serological test segment is predicted to dominate the global lyme disease diagnostics market during the forecast period due to the frequent practice and routine tests for the laboratories and hospitals to diagnose Lyme disease.
The urine antigen tests segment is another lucrative segment in the global lyme disease diagnostics market and is estimated to register a healthy growth rate during the forecast period.
Lyme disease diagnostics market - By Diagnostic Technologies:
Based on technologies, the molecular diagnostic segment was the market leader in the global lyme disease diagnostics market in 2020 and is estimated to continue its lead throughout the forecast period. Advanced laboratories for the disease tests and healthcare facilities' availability boost the molecular diagnostic segment during the forecast period.
Lyme disease diagnostics market - By End User:
Based on the end-user, the hospitals and clinics segment held the majority share with the increasing CAGR over the forecast years, and it is expected to dominate the market. The available commercial test kits for detecting Lyme diseases are expected to propel the market growth over the forecast period.
Lyme disease diagnostics market - By Region
The Middle East and Africa
Geographically, the North America Lyme disease diagnostics market is estimated to play the leading role in the global market during the forecast period and is majorly driven by the factors such as addressing the growing prevalence of Lyme diseases, identifying innovative ways of diagnosing Lyme disease, and improving healthcare facilities. Research and development activities on Lyme disease are anticipated to provide opportunities for the players in the North American market.
The European market is anticipated to be the second-largest regional market globally and is projected to grow at a promising rate during the forecast period. An increase in lyme disease prevalence, growing awareness among people regarding lyme diseases, and increasing investments are expected to drive the European market.
The Asia Pacific market is one of the fastest-growing regional markets globally and is estimated to grow at the highest CAGR during the forecast period. Factors such as the rising prevalence of lyme diseases, the emergence of new lyme diagnostic tests, and the increasing focus on developing healthcare facilities to provide better healthcare treatments for the people in this region are expected to propel the market growth. Rising disposable income in urban areas is also a factor driving the growth rate of the market.
The Middle East and Africa Lyme disease diagnostics market are expected to register a steady growth rate during the forecast period. The increasing prevalence of Lyme diseases and support by the government to improve healthcare facilities are anticipated to fuel the growth rate of the market in this region.
KEY MARKET PARTICIPANTS:
Some of the prominent companies operating in the global Lyme disease diagnostics market profiled in the report are Boulder Diagnostics, Immunetics Inc., GlaxoSmithKline Pharmaceuticals Ltd, Bio-Rad Laboratories, Alere Inc. (ALR), Roche Diagnostics International Ltd, Graphene Frontiers, Covance Inc., Affymetrix Inc., Siemens AG, Baxter International Inc., and Fresenius Medical Care AG & Co.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com